@article{article, title  = {{Dupilumab safety and efficacy in a phase III open-label extension trial in children 6–11 years of age with severe atopic dermatitis}},

 publisher = {{Springer Science and Business Media LLC}},

 url = {{https://eprints.whiterose.ac.uk/id/eprint/204730 }},

 year = {{2023}},

 month = {{9}},

 author = {{Cork MJ and Thaçi D and Eichenfield LF and Arkwright PD and Chen Z and Thomas RB and Kosloski MP and Dubost-Brama A and Prescilla R and Bansal A and Levit NA}},

 doi = {{10.1007/s13555-023-01016-9}},

 volume = {{13}},

 journal = {{Dermatology and Therapy}},

 pages = {{2697-2719}},

 note = {{Accessed on 2024/12/22}}}